Stephen Simes
Director/Board Member at CYTODYN INC.
Net worth: - $ as of 30/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Steven Morris | M | 60 |
Biolife4d Corp.
 Biolife4d Corp. BiotechnologyHealth Technology Biolife4d Corp. engages in biotechnology services. It focuses on leveraging advances in life sciences and tissue engineering to three-dimensional bioprint a viable human heart suitable for transplant. The company was founded by Steven Morris on November 14, 2016 and is headquartered in Buffalo Grove, IL. | 8 years |
| Michael D. Mulholland | M | 72 | 12 years | |
| Oz Adler | M | 36 | 7 years | |
| Tanya Urbach | F | 57 | 3 years | |
| Cyrus Arman | M | 43 | 2 years | |
| Amitay Weiss | M | 62 | 4 years | |
| Itschak Shrem | M | 76 | 4 years | |
| Tyler Blok | M | 37 | 2 years | |
| Ryan Dunlap | M | 54 | 2 years | |
| Lishomwa Ndhlovu | M | 54 | 3 years | |
| Lior Vider | M | 47 | 4 years | |
| Liat Sidi | F | 50 | 4 years | |
| Christopher P. Recknor | M | 59 | 4 years | |
| Karen Brunke | M | 72 | 2 years | |
| Lisa M. Kelley | F | 57 |
Biolife4d Corp.
Biolife4d Corp. BiotechnologyHealth Technology Biolife4d Corp. engages in biotechnology services. It focuses on leveraging advances in life sciences and tissue engineering to three-dimensional bioprint a viable human heart suitable for transplant. The company was founded by Steven Morris on November 14, 2016 and is headquartered in Buffalo Grove, IL. | 2 years |
| Melissa Palmer | M | - | 1 years | |
| Joseph Meidling | M | - | 3 years | |
| Jeffrey Adam Morgan | M | 49 |
Biolife4d Corp.
Biolife4d Corp. BiotechnologyHealth Technology Biolife4d Corp. engages in biotechnology services. It focuses on leveraging advances in life sciences and tissue engineering to three-dimensional bioprint a viable human heart suitable for transplant. The company was founded by Steven Morris on November 14, 2016 and is headquartered in Buffalo Grove, IL. | 7 years |
| Seenu Srinivasan | M | - | 3 years | |
| Cristina de Leon | F | - | - | |
| Jeffrey A. Hechtman | M | - |
Biolife4d Corp.
Biolife4d Corp. BiotechnologyHealth Technology Biolife4d Corp. engages in biotechnology services. It focuses on leveraging advances in life sciences and tissue engineering to three-dimensional bioprint a viable human heart suitable for transplant. The company was founded by Steven Morris on November 14, 2016 and is headquartered in Buffalo Grove, IL. | - |
| Kate Lewis | F | 62 |
Biolife4d Corp.
Biolife4d Corp. BiotechnologyHealth Technology Biolife4d Corp. engages in biotechnology services. It focuses on leveraging advances in life sciences and tissue engineering to three-dimensional bioprint a viable human heart suitable for transplant. The company was founded by Steven Morris on November 14, 2016 and is headquartered in Buffalo Grove, IL. | 4 years |
| Mitchell Cohen | M | 68 | - | |
| Jacob P. Lalezari | M | 65 | 1 years | |
| Lynne Bolduc | F | - |
Biolife4d Corp.
Biolife4d Corp. BiotechnologyHealth Technology Biolife4d Corp. engages in biotechnology services. It focuses on leveraging advances in life sciences and tissue engineering to three-dimensional bioprint a viable human heart suitable for transplant. The company was founded by Steven Morris on November 14, 2016 and is headquartered in Buffalo Grove, IL. | - |
| James Marken | M | 61 | 17 years | |
| Wesley Ramjeet | M | 57 |
Biolife4d Corp.
Biolife4d Corp. BiotechnologyHealth Technology Biolife4d Corp. engages in biotechnology services. It focuses on leveraging advances in life sciences and tissue engineering to three-dimensional bioprint a viable human heart suitable for transplant. The company was founded by Steven Morris on November 14, 2016 and is headquartered in Buffalo Grove, IL. | 2 years |
| Scott Hansen | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Philip Donenberg | M | 63 |
RestorGenex Corp.
 RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL.
Unimed Pharmaceuticals LLC
 Unimed Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Unimed Pharmaceuticals, Inc. manufactured pharmaceutical products. It provided multiple indications in the therapeutic areas of cardiology, men's health, HIV and other infectious diseases. The company was founded in 1999 and was headquartered in Marietta, GA. | 21 years |
| Antonio Migliarese | M | 41 | 4 years | |
| Stephen Sherwin | M | 75 |
Ceregene, Inc.
 Ceregene, Inc. Pharmaceuticals: MajorHealth Technology Ceregene, Inc. develops pharmaceutical products for neurodegenerative disorders. The company was founded in January 2001 and it is headquartered in Richmond, CA. | 12 years |
| Charlotte C. Arnold | F | 59 | 7 years | |
| Gilad Bar-Lev | M | - | - | |
| Scott A. Kelly | M | 54 | 5 years | |
| Arthur S. Przybyl | M | 67 | 11 years | |
| Timothy Boris | M | 55 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 4 years |
| Robert Dudley | M | 69 |
Unimed Pharmaceuticals LLC
Unimed Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Unimed Pharmaceuticals, Inc. manufactured pharmaceutical products. It provided multiple indications in the therapeutic areas of cardiology, men's health, HIV and other infectious diseases. The company was founded in 1999 and was headquartered in Marietta, GA. | 7 years |
| Ascher Shmulewitz | M | 67 | 7 years | |
| Ross J. Mangano | M | 78 | 2 years | |
| Michael C. Snabes | M | 75 | 8 years | |
| Eric So | M | 49 | 2 years | |
| Nelson K. Stacks | M | 53 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | - |
| John L. Gainer | M | 85 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | - |
| Yafit Stark | M | 70 | 5 years | |
| Heber Hilel Elran | M | 44 | 3 years | |
| Rob W. Schrepfer | M | 52 | - | |
| Yael Schwartz | M | 75 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 1 years |
| Amit Berger | M | 59 | 6 years | |
| Joanne Zborowski | F | - | - | |
| Mark Groussman | M | 51 | 1 years | |
| Todd Violette | M | - | - | |
| Zohar Heiblum | M | 69 | 7 years | |
| David G. Kalergis | M | 75 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | - |
| Nitya G. Ray | M | 71 | 4 years | |
| Tracy Marshbanks | M | 60 | 12 years | |
| Sol Barer | M | 76 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 3 years |
| Isaac Blech | M | 73 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 3 years |
| Thomas Penn | M | 78 | 11 years | |
| Jerold Howard Rubinstein | M | 86 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 3 years |
| Fred Holubow | M | 85 | 19 years | |
| John T. Potts | M | 92 | 4 years | |
| Steven J. Bell | M | - | - | |
| Edward C. Rosenow | M | 89 | 16 years | |
| Peter Kjaer | M | 64 | - | |
| Rex Bright | M | 84 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 2 years |
| David Sherris | M | 71 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 2 years |
| Louis Sullivan | M | 90 | 19 years | |
| Mark A. Weinberg | M | - |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 2 years |
| Sukumar Nagendran | M | 58 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 2 years |
| Moshe Revach | M | 85 | 2 years | |
| Ari Shamiss | M | 65 | - | |
| Patricia Fuller | F | - | - | |
| Lior Amit | M | 58 | - | |
| Patricia M. Adams | F | - | - | |
| Alan Levin | M | 62 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | - |
| Sandra J. Croak-Brossman | M | - | - | |
| David R. Jones | M | 60 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | - |
| Jeffrey W. Winkelman | M | - | - | |
| Andrea Loewen-Rodriguez | F | 57 |
Ceregene, Inc.
Ceregene, Inc. Pharmaceuticals: MajorHealth Technology Ceregene, Inc. develops pharmaceutical products for neurodegenerative disorders. The company was founded in January 2001 and it is headquartered in Richmond, CA. | 1 years |
| David Silverman | M | 56 | - | |
| Donald P. Dizon | M | - | - | |
| Zeev Bronfeld | M | 71 | 5 years | |
| Joshua Blacher | M | 52 | 1 years | |
| Mark T. Giles | M | 69 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | - |
| Herbert Conrad | M | 91 | - | |
| Thomas Byrne | M | 67 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | - |
| Joao Siffert | M | 60 |
Ceregene, Inc.
Ceregene, Inc. Pharmaceuticals: MajorHealth Technology Ceregene, Inc. develops pharmaceutical products for neurodegenerative disorders. The company was founded in January 2001 and it is headquartered in Richmond, CA. | 4 years |
| Robert W. Adams | M | 73 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | - |
| Mehdi Gasmi | M | 57 |
Ceregene, Inc.
Ceregene, Inc. Pharmaceuticals: MajorHealth Technology Ceregene, Inc. develops pharmaceutical products for neurodegenerative disorders. The company was founded in January 2001 and it is headquartered in Richmond, CA. | 8 years |
| Katherine Bishop | M | 58 |
Ceregene, Inc.
Ceregene, Inc. Pharmaceuticals: MajorHealth Technology Ceregene, Inc. develops pharmaceutical products for neurodegenerative disorders. The company was founded in January 2001 and it is headquartered in Richmond, CA. | 8 years |
| William D. Milling | M | - | - | |
| John F. Moynahan | M | 66 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 5 years |
| Raymond T. Bartus | M | - |
Ceregene, Inc.
Ceregene, Inc. Pharmaceuticals: MajorHealth Technology Ceregene, Inc. develops pharmaceutical products for neurodegenerative disorders. The company was founded in January 2001 and it is headquartered in Richmond, CA. | 11 years |
| Robert J. Jamnick | M | 66 | 8 years | |
| Arie Webber | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 73 | 76.84% |
| Israel | 22 | 23.16% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Stephen Simes
- Personal Network
